Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2017, Pages

  Mahdi Rogers, Mohamed ^a   Brassington, Ruth ^b   Gunn, Angela A ^b   van Doorn, Pieter A ^c   Hughes, Richard A C ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PLACEBO; PREDNISONE; RITUXIMAB; ANTIINFLAMMATORY AGENT; BETA INTERFERON; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

CLINICAL PROTOCOL; DRUG INDUSTRY; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MOTOR NERVE CONDUCTION; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL ANALOG SCALE; META ANALYSIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON BETA-1A; INTERFERON-BETA; METHOTREXATE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85019077796     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003280.pub5     Document Type: Review

References (182)

1. Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985;35(8):1173-6. [PUBMED: 4022350]2859671
2. Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53(1):57-61. [PUBMED: 10408537]2859673
3. Gorson K, Hughes R, Cros D, Pollard J, Vallat J, Riester K, et al. Efficacy of interferon beta-1a in patients chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 2008;70(11 Suppl 1):A369. 2859675
4. Gorson KC, Hughes RAC, Cros DP, Pollard JD, Vallat J-M, Riester K, et al. Efficacy of interferon beta1A in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Journal of the Peripheral Nervous System 2008;13(2):170. 2859676
5. Hughes RAC, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, et al. Avonex CIDP Study Group. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010;74(8):651-7. [PUBMED: 20177118]2859677
6. EUCTR2005-003382-16-GB. Pilot randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial). - RMC Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-003382-16-GB (accessed 4 December 2015). 2859679
7. Mahdi-Rogers M, for the Randomised Methotrexate Chronic Inflammatory Demyelinating Polyradiculoneuropathy (RMC) Trial Group. A pilot randomised controlled trial of methotrexate for CIDP: Lessons for future trials. Journal of the Peripheral Nervous System: JPNS 2008;13(2):176. 2859680
8. Pace AA, Hughes RAC, van Schaik IN, Hobart JC, for the RMC Trial Group. Randomised trial of methotrexate in CIDP (RMC) study: Did the measurement of strength prove to be a weakness?. Journal of the Peripheral Nervous System: JPNS 2009;14(Suppl s2):116-7. 2859681
9. RMC trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurology 2009; Vol. 8, issue 2:158-64. [PUBMED: 19136303]2859682
10. NCT01757574. Alemtuzumab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). clinicaltrials.gov/show/NCT01757574 (accessed 10 January 2013; December 2015). 2859698
11. NCT00962429. Lipoic acid to treat chronic inflammatory demyelinating polyneuropathy - a randomised, double-blind, placebo controlled pilot study. clinicaltrials.gov/show/NCT00962429 (accessed 10 July 2016). 2859696
12. Hu JY, Chen JL, Zhang ZH. Clinical observation on treatment of 10 patients with chronic inflammatory demyelinating polyneuropathy by gullong tongluo capsule combined with prednisone. Zhongguo Zhong Xi Yi Jie He Za Zhi (Chinese) July 2009;29(7):649-51. 2859684
13. Hartung H, Sobue G, Dalakas M, Latov N, Leger JM, Merkies I, et al. Fingolimid (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): study design of the phase 3 FORCIDP trial. Neurology 2014;82(Suppl):Poster no: P6.103. 5491045
14. Hughes R, Dalakas M, Latov N, Léger J-M, Merkies I, Nobile-Orazio E, et al. Fingolimod (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial. Journal of the Neurological Sciences 2013;333(Suppl 1):e361. [EMBASE: 71188889]2859686
15. Hughes RAC, Dalakas M, Latov N, Leger J-M, Merkies ISJ, Nobile-Orazio E, et al. Oral fingolimod (FTY720) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial. Journal of the Peripheral Nervous System: JPNS 2013;18(Suppl s2):S48-9. [EMBASE: 71124949]2859687
16. NCT01625182. Evaluate efficacy and safety of fingolimod 0.5 mg orally once daily versus placebo in chronic inflammatory demyelinating polyradiculoneuropathy patients. clinicaltrials.gov/show/NCT01625182 (accessed 10 January 2013; December 2015). 2859688
17. NCT00278629. Hematopoetic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy. clinicaltrials.gov/show/NCT00278629 (accessed 10 January 2013; December 2015). 2859694
18. JPRN-UMIN000000674. Cyclosporin A (Neoral) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) requiring repetitive administration of high-dose intravenous immunoglobulin. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000000674 (accessed 4 December 2015). 2859690
19. NCT012494505. Interest of Mycophenolate for CIDP Weaning (MYCOPID). clinicaltrials.gov/ct2/show/NCT02494505 (accessed 16 June 2016). 5491047
20. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 1991;41(5):617-8. [PUBMED: 2027473]
21. Ahlmén J, Andersen O, Hallgren G, Peilot B. Positive effect of tacrolimus (FK 506) in a case of CIDP. 3rd International Conference on New Trends in Clinical and Experimental Immunosuppression 1998:110.
22. Ahmed Z, Powell R, Llewelyn G, Anstey A. Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF α therapy for chronic plaque psoriasis. BMJ Case Reports 2011, issue pii: bcr0820114674. [DOI: 10.1136/bcr.08.2011.4674; PUBMED: 22674940]
23. Allen JA, Sufit R, Ajroud-Driss S, Burt R. Nonmyeloablative autologous hematopoetic stem cell transplant for the treatment of CIDP: An interim report. Journal of the Peripheral Nervous System: JPNS 2013;18(Suppl):S5.
24. Alshekhlee A, Basiri K, Miles JD, Ahmad SA, Katirji B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle & Nerve 2010;41(5):723-7. [PUBMED: 20405504]
25. Austin JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958;81(2):157-92. [PUBMED: 13572689]
26. Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. Journal of Neurology, Neurosurgery, and Psychiatry 2008;79(5):612-4. [PUBMED: 18408093]
27. Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle & Nerve 1998;21(4):454-60. [PUBMED: 9533779]
28. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Archives of Neurology 1989;46(8):878-84. [PUBMED: 2757528]
29. Barreira AA, Marques W Jr, Rezende C, de Souza DGB, Voltarelli J. Autologous stem cell transplantation of a patient with chronic demyelinating neuropathy and persistent conduction block. Journal of the Peripheral Nervous System: JPNS 2007;12(s1):7.
30. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2(8604):179-83. [PUBMED: 2899660]
31. Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. Journal of Neurology, Neurosurgery, and Psychiatry 2010;81(6):634-6. [PUBMED: 20176598]
32. Benedetti L, Grandis M, Nobbio L, Beronio A, Ghiglione E, Manzino M, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle & Nerve 2004;29(5):748-9. [PUBMED: 15116381]
33. Benedetti L, Franciotta D, Beronio A, Cadenotti L, Gobbi M, Mancardi GL, et al. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle & Nerve 2008; Vol. 38, issue 2:1076-7. [PUBMED: 18642360]
34. Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. Journal of Neurology, Neurosurgery, and Psychiatry 2011;82(3):306-8. [PUBMED: 20639381]
35. Joint Formulary Committee. British National Formulary. 8th Edition. London: BMJ Group and Pharmaceutical Press, September 2014.
36. Bodley-Scott DD. Chronic inflammatory demyelinating polyradiculoneuropathy responding to rituximab. Practical Neurology 2005;5(4):242-5. [DOI: 10.1111/j.1474-7766.2005.00328.x; EMBASE: 2005372287 ]
37. Bouchard C, Lacroix C, Planté V, Adams D, Chedru F, Guglielmi JM, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999;52(3):498-503. [PUBMED: 10025777]
38. Brannagan TH, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002;58(12):1856-8. [PUBMED: 12084892]
39. Briani C, Zara G, Zambello R, Trentin L, Rana M, Zaja F. Rituximab-responsive CIDP. European Journal of Neurology 2004;11(11):788. [PUBMED: 15525302]
40. Camdessanché J-P, Ferraud K, Lagrange E, Viala K, Chan V, Guy N, et al. Multicentre, randomised, open-label trial to compare efficacy and tolerance of corticosteroids and IVIg in patients with CIDP on a one-year follow-up. Journal of the Peripheral Nervous System: JPNS 2013;18(Suppl):S17-8.
41. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56(1):94-6. [PUBMED: 11148242]
42. Chin RL, Sherman WH, Sander HW, Hays AP, Latov N. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences 2003;210(1-2):19-21. [PUBMED: 12736082]
43. Chiò A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. Journal of Neurology, Neurosurgery, and Psychiatry 2007; Vol. 78, issue 12:1349-53. [PUBMED: 17494979]
44. Choudhary PP, Thompson N, Hughes RAC. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1995;242(4):252-3. [PUBMED: 7798127]
45. Cochrane Editorial Unit. Cochrane Editorial and Publishing Resource (updated May 2015). (community.cochrane.org/editorial-and-publishing-policy-resource) (accessed 31 March 2017).
46. Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, Benedetti L, et al. Italian Network for CIDP Register. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. European Journal of Neurology 2011;18(12):1417-21. [PUBMED: 21819489]
47. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996;46(6):1607-12. [PUBMED: 8649558]
48. D'Amico A, Catteruccia M, De Benedetti F, Vivarelli M, Colucci M, Cascioli S, et al. Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. European Journal of Paediatric Neurology: EJPN 2012;16(3):301-3. [PUBMED: 21903431]
49. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Annals of Neurology 1981;9(Suppl):134-45. [PUBMED: 7224612]
50. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology 2009; Vol. 65, issue 3:286-93. [PUBMED: 19334068]
51. Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, van der Pol WL, Notermans NC, et al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 2014;83(23):2124-32. [PUBMED: 25378677 ]
52. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clinic Proceedings 1975;50(11):621-37. [PUBMED: 1186294]
53. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. New England Journal of Medicine 1986;314(8):461-5. [PUBMED: 3511382]
54. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 1994;36(6):838-45. [PUBMED: 7998769]
55. Dyck PJ, Hughes RAC, O'Brien PC. Quantitating overall neuropathic symptoms, impairments, and outcomes. In: Dyck PJ, Thomas PK editor(s). Peripheral Neuropathy. 4th Edition. Philadelphia: Elsevier Saunders, 2005:1031-52.
56. Díaz-Manera J, Rojas-García R, Gallardo E, Illa I. Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient. Muscle & Nerve 2009;39(3):386-8. [PUBMED: 19208395]
57. Echaniz-Laguna A, de Séze J, Chanson JB. Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. Journal of Neurology, Neurosurgery, and Psychiatry 2012;83(7):699-705. [PUBMED: 22577230 ]
58. Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Journal of the Peripheral Nervous System: JPNS 2005;10(3):220-8. [PUBMED: 16221283]
59. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Journal of the Peripheral Nervous System: JPNS 2006; Vol. 11, issue 1:1-8. [PUBMED: 16519777]
60. Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies, Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Journal of the Peripheral Nervous System: JPNS 2010; Vol. 17, issue 3:356-63. [PUBMED: 20456730]
61. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD001797.pub3]
62. Hughes RAC on behalf of the CIDP and MMN Trial Group. 129th ENMC International Workshop: Clinical Trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy, 27th October 2004, Schiphol airport, The Netherlands. Neuromuscular Disorders: NMD 2005;15(4):321-5. [PUBMED: 15792873]
63. Erdener SE, Nurlu G, Gocmen R, Erdem-Ozdamar S, Kurne A. Remission with fingolimod in a case of demyelinating polyneuropathy. Muscle & Nerve 2014;50(4):615-7. [PUBMED: 24909140]
64. Fialho D, Chan YC, Allen DC, Reilly MM, Hughes RA. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. Journal of Neurology, Neurosurgery, and Psychiatry 2006; Vol. 77, issue 4:544-7. [PUBMED: 16543541 ]
65. Gladstone DE, Prestrud AA, Brannagan TH 3rd. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System: JPNS 2005;10(1):11-6. [PUBMED: 15703014 ]
66. Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998;51(6):1735-8. [PUBMED: 9855536]
67. Gorson KC, Allam G, Simovic D, Ropper AH. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology 1997;48(3):777-80. [PUBMED: 9065566]
68. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004;63(4):715-7. [PUBMED: 15326250]
69. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle & Nerve 2007;35(1):66-9. [PUBMED: 16967492]
70. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(8):973-6. [PUBMED: 16574730]
71. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119(Pt 4):1055-66. [PUBMED: 8813270]
72. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind placebo-controlled cross-over study. Brain 1996;119(Pt 4):1067-77. [PUBMED: 8813271]
73. Hahn AF, Hartung H-P, Dyck PJ. Chronic Inflammatory Demyelinating Polyradiculoneuropathy. In: Dyck PJ, Thomas PK editor(s). Peripheral Neuropathy. Fourth. Vol. 2, Philadelphia: Elsevier, 2005:2221-53.
74. Hamon MA, Nicolas G, Deviere F, Letournel F, Dubas F. Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature [Neuropathie démyélinisante au cours d'un traitement par anti-TNF alpha et revue de la litérature]. Revue Neurologique 2007;163(12):1232-5. [PUBMED: 18355471]
75. Hefter H, Sprenger KB, Arendt G, Hafner D. Treatment of chronic relapsing inflammatory demyelinating polyneuropathy by cyclosporin A and plasma exchange. A case report. Journal of Neurology 1990;237(5):320-3. [PUBMED: 2230850]
76. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
77. Hirst C, Raasch S, Llewelyn G, Robertson N. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(6):800-2. [PUBMED: 16705208]
78. Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 1990;53(4):327-30. [PUBMED: 2341846 ]
79. Holman R, Lindeboom R, Vermeulen M, de Haan RJ. The AMC Linear Disability Score project in a population requiring residential care: psychometric properties. Health and Quality of Life Outcomes 2004; Vol. 2:42. [PUBMED: 15291958]
80. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy. Archives of Neurology 1992;49(6):612-6. [PUBMED: 1317700]
81. Hughes R, Bensa S, Willison H, van Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 2001;50(2):195-201. [PUBMED: 11506402]
82. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): a randomised placebo-controlled trial. Lancet Neurology 2008; Vol. 7, issue 2:136-44. [PUBMED: 18178525]
83. Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD002062.pub3]
84. Jasmin R, Sockalingam S, Shahrizaila N, Cheah TE, Zain AA, Goh KJ. Successful treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in systemic lupus erythematosus (SLE) with oral cyclophosphamide. [Review]. Lupus 2012;21(10):1119-23. [PUBMED: 22433918]
85. Kasamon YL, Nguyen TN, Chan JA, Nascimento AF. EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency. American Journal of Hematology 2002;69(4):289-93. [PUBMED: 11921025]
86. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54(3):615-20. [PUBMED: 10680792]
87. Kelly JJ, Kyle RA, O'Brien PC, Dyck PJ. The prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981;31(11):1480-3. [PUBMED: 6273767]
88. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009; Vol. 339:b2480. [PUBMED: 2714688]
89. Kilidireas C, Anagnostopoulos A, Karandreas N, Mouselimi L, Dimopoulos MA. Rituximab therapy in monoclonal IgM-related neuropathies. Leukemia and Lymphoma 2006;47(5):859-64. [PUBMED: 16753870]
90. Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology 1986;36(1):35-9. [PUBMED: 3941781]
91. Kleyman I, Brannagan TH 3rd. Treatment of chronic inflammatory demyelinating polyneuropathy. Current Neurology and Neuroscience Reports 2015;15(7):47. [PUBMED: 26008811]
92. Knecht H, Baumberger M, Tobòn A, Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004;63(4):730-2. [PUBMED: 15326255]
93. Kolkin S, Nahman NS Jr, Mendell JR. Chronic nephrotoxicity complicating cyclosporin treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987;37(1):147-9. [PUBMED: 3796829]
94. Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves M, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences 2009;277(1-2):1-8. [PUBMED: 19091330]
95. Kuitwaard K, van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA. Recurrent Guillain-Barré syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 2009; Vol. 80, issue 1:56-9. [PUBMED: 18931012]
96. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, Naegeli C, Ochsner F, Erne B, et al. Interferon-beta 1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999;53(6):1364-5. [PUBMED: 10522905]
97. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. New England Journal of Medicine 2005;352(13):1343-56. [PUBMED: 15800230]
98. Laughlin RS, Dyck PJ, Melton LJ 3rd, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; Vol. 73, issue 1:39-45. [PUBMED: 19564582]
99. Leitch MM, Sherman WH, Brannagan TH 3rd. Fludarabine in the treatment of refractory chronic inflammatory demyelinating neuropathies. Journal of Clinical Neuromuscular Disease 2015;17(1):1-5. [PUBMED: 26301372 ]
100. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982;32(9):958-64. [PUBMED: 7202168]
101. Llewelyn JG, Reilly MM, Krishnan AV, Doran M, Ryan A, Robertson NP. Alemtuzumab in the treatment of IVIg-dependent chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System 2009; Vol. 14, issue s2:90-1. [DOI: 10.1111/j.1529-8027.2009.00212.x]
102. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-blocker therapy. Archives of Neurology 2009;66(4):490-7. [PUBMED: 19364934]
103. Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. Journal of Neurology, Neurosurgery, and Psychiatry 1999;66(5):677-80. [PUBMED: 10209187]
104. Lunn MPT. Rituximab usage in CIDP: A retrospective e-mail based data collection. Journal of the Peripheral Nervous System: JPNS 2009; Vol. 14, issue s2:92. [DOI: 10.1111/j.1529-8027.2009.00212.x]
105. Lunn M, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD002827.pub4]
106. Léger J-M. A review of the medical management of chronic inflammatory demyelinating polyradiculoneuropathy. Expert Opinion on Pharmacotherapy 2005;6(4):569-82. [PUBMED: 15934883]
107. Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, et al. RIMAG Study Group (France and Switzerland). Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 2013;80(24):2217-25. [PUBMED: 23667063]
108. Mahattanakul W, Crawford TO, Griffin JW, Goldstein JM, Cornblath DR. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. Journal of Neurology, Neurosurgery, and Psychiatry 1996;60(2):185-7. [PUBMED: 8708650]
109. Mahdi-Rogers M, Hughes RAC, Kazmi M, Ferner R. Autologous peripheral blood progenitor cell transplantation for Chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System: JPNS 2007;12(s1):55. [DOI: 10.1111/j.1529-8027.2007.00123.x]
110. Mahdi-Rogers, M, Al-Chalabi A, Hughes RAC. Prevalence and morbidity of chronic inflammatory neuropathies in South East England. Journal of the Peripheral Nervous System: JPNS 2008; Vol. 13, issue 2:176-7. [DOI: 10.1111/j.1529-8027.2008.00174.x]
111. Mahdi-Rogers M, Kazmi M, Ferner R, Hughes RA, Renaud S, Steck AJ, et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. Journal of the Peripheral Nervous System: JPNS 2009; Vol. 14, issue 2:118-24. [PUBMED: 19691534]
112. Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. European Journal of Neurology 2014;21(1):28-33. [PUBMED: 23679015]
113. Markvardsen LH, Debost JC, Harbo T, Sindrup SH, Andersen H, Christiansen I, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology 2013;20(5):836-42. [PUBMED: 23294032]
114. Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 2010;257(6):913-9. [PUBMED: 20049473]
115. Martina IS, van Doorn PA, Schmitz PI, Meulstee J, van der Meché FG. Chronic motor neuropathies: response to interferon-beta 1a after failure of conventional therapies. Journal of Neurology, Neurosurgery, and Psychiatry 1999;66(2):197-201. [PUBMED: 10071099]
116. Marzo ME, Tintoré M, Fabregues O, Montalbán X, Codina A. Chronic inflammatory demyelinating polyradiculoneuropathy during treatment with interferon-alpha. Journal of Neurology, Neurosurgery, and Psychiatry 1998;65(4):604. [PUBMED: 9771799]
117. Matsuda M, Hoshi K, Gono T, Morita H, Ikeda S. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Neurological Sciences 2004;224(1-2):29-35. [PUBMED: 15450768]
118. Matsuse D, Ochi H, Tashiro K, Nomura T, Murai H, Taniwaki T, et al. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferon beta-1b therapy in a patient with childhood-onset multiple sclerosis. Internal Medicine (Tokyo, Japan) 2005;44(1):68-72. [PUBMED: 15704667]
119. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987;110(Pt 6):1617-30. [PUBMED: 3427403]
120. Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD003906.pub4]
121. Melzer N, Meuth SG. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. [Review]. Clinical and Experimental Immunology 2014;175(3):359-72. [PUBMED: 24032475 ]
122. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56(4):445-9. [PUBMED: 11222785]
123. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle & Nerve 2000;23(3):433-5. [PUBMED: 10679722]
124. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA, Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72(5):596-601. [PUBMED: 11971045]
125. Monaco S, Turri E, Zanusso G, Maistrello B. Treatment of inflammatory and paraproteinemic neuropathies. Current Drug Targets. Immune, Endocrine and Metabolic Disorders 2004;4(2):141-8. [PUBMED: 15180454]
126. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. Journal of the Neurological Sciences 2001;185(2):119-22. [PUBMED: 11311292]
127. Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. European Journal of Neurology 2001; Vol. 8, issue 2:157-65. [PUBMED: 11284994 ]
128. Münch C, Anagnostou P, Meyer R, Haas J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. Journal of the Neurological Sciences 2007;256(1-2):100-2. [PUBMED: 17382963]
129. Nobile-Orazio E. Treatment of dys-immune neuropathies. Journal of Neurology 2005;252(4):385-95. [PUBMED: 15834625]
130. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurology 2012;11(6):493-502. [PUBMED: 2012287474]
131. Odaka M, Tatsumoto M, Susuki K, Hirata K, Yuki N. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. Journal of Neurology, Neurosurgery, and Psychiatry 2005;76(8):1115-20. [PUBMED: 16024890]
132. Oh SJ, Joy JL, Kuruoglu R. 'Chronic sensory demyelinating neuropathy': chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 1992;55(8):677-80. [PUBMED: 1326601]
133. Oh SJ, Kurokawa K, de Almeida DF, Ryan HF Jr, Claussen GC. Subacute inflammatory demyelinating polyneuropathy. Neurology 2003;61(11):1507-12. [PUBMED: 14663033]
134. Ormerod IE, Waddy HM, Kermode AG, Murray NM, Thomas PK. Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study. Journal of Neurology, Neurosurgery, and Psychiatry 1990;53(9):789-93. [PUBMED: 2174078]
135. Oyama Y, Sufit R, Loh Y, Statkute L, Yaung K, Quigley K, et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology 2007;69(18):1802-3. [PUBMED: 17967996]
136. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50(6):1778-83. [PUBMED: 9633727]
137. Pavesi G, Cattaneo L, Marbini A, Gemignani F, Mancia D. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 2002;249(6):777-9. [PUBMED: 12173577]
138. Press R, Askmark H, Svenningsson A, Andersen O, Axelson HW, Strömberg U, et al. Autologous haematopoietic stem cell transplantation: A viable treatment option for CIDP. Journal of Neurology, Neurosurgery, and Psychiatry 2014;85(6):618-24. [PUBMED: 24262917]
139. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. Journal of the Neurological Sciences 1976;27(4):427-58. [PUBMED: 1262904]
140. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352(9139):1498-504. [PUBMED: 9820297]
141. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56(12):1628-36. [PUBMED: 11425926]
142. Radziwill AJ, Kuntzer T, Fuhr P, Steck AJ. Long term follow up in chronic inflammatory demyelinating polyneuropathy (CIDP) under interferon beta-1a (IFN-b1a) and intravenous immunoglobulin (IVIg). Journal of Neurology, Neurosurgery, and Psychiatry 2001;70:273.
143. Radziwill AJ, Schweikert K, Kuntzer, Fuhr P, Steck AJ. Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: An open label study. European Journal of Neurology 2006; Vol. 56, issue 1:37-8. [PUBMED: 16914929]
144. Reményi P, Masszi T, Borbényi Z, Soós J, Siklós L, Englelhardt JI. CIDP cured by allogeneic hematopoietic stem cell transplantation. European Journal of Neurology 2007; Vol. 14, issue 8:e1-e2. [PUBMED: 17661987]
145. The Nordic Cochrane Centre, The Cochrane Collaboration. Reference Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
146. Rose WN, Dwyre DM, Erickson YO, Klutts JS. Chronic inflammatory demyelinating polyradiculoneuropathy refractory to multiple treatment modalities responds to rituximab. American Journal of Clinical Pathology 2010;134:510-1.
147. Ruts L, van Koningsveld R, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 2005;65(1):138-40. [PUBMED: 16009902]
148. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010;74(21):1680-6. [PUBMED: 20427754]
149. Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA. Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscular Disorders 2000;10(6):398-406.
150. Sadnicka A, Reilly MM, Mummery C, Brandner S, Hirsch N, Lunn MP. Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. Journal of Neurology, Neurosurgery, and Psychiatry 2011;82(2):230-2. [PUBMED: 20462915]
151. Sanz PG, García Méndez CV, Cueto AL, Silva VB, Walther JC, Diez RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment. Rheumatology International 2012;32(12):4061-3. [PUBMED: 21922339 ]
152. Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, Jackson CE, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle & Nerve 1999;22(5):560-6. [PUBMED: 10331353]
153. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle & Nerve 2001;24(3):311-24. [PUBMED: 11353415]
154. Saperstein DS. Chronic acquired demyelinating polyneuropathies. Seminars in Neurology 2008;28(2):168-84. [PUBMED: 18351519]
155. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patient with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118(Pt 2):359-68. [PUBMED: 7735878]
156. Stork ACJ, Lunn MPT, Nobile-Orazio E, Notermans NC. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD005376.pub3]
157. Stübgen JP. A review of the use of biological agents for chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Neurological Sciences 2013;326(1-2):1-9. [PUBMED: 23337197]
158. Takeuchi A, Shirai S, Horiuchi K, Takahashi I, Matsushima M, Hirotani M, et al. [Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4h) and trough levels]. [Japanese]. Rinsho Shinkeigaku [Clinical Neurology] 2012;52(3):172-7. [PUBMED: 22453042 ]
159. Thomas PK, Claus D, Jaspert A, Workman JM, King RH, Larner AJ, et al. Focal upper limb demyelinating neuropathy. Brain 1996;119(Pt 3):765-74. [PUBMED: 8673489]
160. Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology 1996; Vol. 243, issue 3:280-5. [PUBMED: 8936360]
161. Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. European Journal of Neurology 2002;9(6):683-5. [PUBMED: 12453086]
162. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD003217.pub5]
163. Vallat JM, Hahn AF, Léger JM, Cros DP, Magy L, Tabaraud F, et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003;60(8 Suppl 3):S23-8. [PUBMED: 12707419 ]
164. Vallat JM, Mathis S, Ghorab K, Milor MA, Richard L, Magy L. Natalizumab as a disease-modifying therapy in chronic inflammatory demyelinating polyneuropathy - a report of three cases. European Neurology 2015;73(5-6):294-302. [DOI: 10.1159/000381767; PUBMED: 25925430]
165. Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies, Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. European Journal of Neurology 2010;17(3):356-63. [PUBMED: 20456730]
166. van Doorn PA. Treatment of Guillain-Barré syndrome and CIDP. Journal of the Peripheral Nervous System: JPNS 2005;10(2):113-27. [PUBMED: 15958124]
167. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011;76(4):337-45. [PUBMED: 21263135]
168. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurology 2010;9(3):245-53. [PUBMED: 20133204]
169. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19(5):604-7. [PUBMED: 3363593]
170. Vanhoutte EK, Latov N, Deng C, Hanna K, Hughes RAC, Bril V, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG - the ICE study. European Journal of Neurology 2013;20(5):748-55. [PUBMED: 22891893]
171. Velardo D, Bianchi F, Mannina D, Mauri E, Comi G, Fazio R. Rituximab in two cases of chronic inflammatory demyelinating polyradiculoneuropathy not responsive to other treatments. Journal of the Peripheral Nervous System: JPNS 2014;19(s1):S34-5.
172. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double blind, placebo controlled study. Journal of Neurology, Neurosurgery, and Psychiatry 1993;56(1):36-9. [PUBMED: 8429321]
173. Vermeulen M, van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72(1):127-8. [PUBMED: 11784845]
174. Vermeulen M, Van Oers MH. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. Journal of Neurology, Neurosurgery, and Psychiatry 2007;78(10):1154. [PUBMED: 17878198]
175. Viala K, Renié L, Maisonobe T, Béhin A, Neil J, Léger JM, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004; Vol. 127, issue Pt 9:2010-7. [PUBMED: 15289267]
176. Waddy HM, Misra VP, King RH, Thomas PK, Middleton L, Ormerod IE. Focal cranial nerve involvement in chronic inflammatory demyelinating polyneuropathy: clinical and MRI evidence of peripheral and central lesions. Journal of Neurology 1989;236(7):400-5. [PUBMED: 2809641]
177. Ware TL, Kornberg AJ, Rodriguez-Casero MV, Ryan MM. Childhood chronic inflammatory demyelinating polyneuropathy: an overview of 10 cases in the modern era. Journal of Child Neurology 2014;29(1):43-8.
178. Wolf C, Menge T, Stenner MP, Meyer zu Hörste G, Saleh A, Hartung HP, et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Archives of Neurology 2010;67(7):881-3. [PUBMED: 20625098]
179. Hughes RAC. Systematic reviews of treatment for inflammatory demyelinating neuropathy. Journal of Anatomy 2002;200(4):331-9. [PUBMED: 12090400]
180. Hughes RAC, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD003280]
181. Hughes RAC, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003280.pub2]
182. Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RAC. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD003280.pub3]